DOCSLIB.ORG

Hospital Standard File Pricing Transparency 2020 0.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hospital Standard File Pricing Transparency 2020 0.Pdf Phoenix Children's Hospital Hospital Standard File Pricing as of Jan. 1, 2020 Service Code Description Rev Code Price 37010001 GEN SURG LEV 1 1ST HR 360 4,222.00 37010002 GEN SURG LEV 1 ADD 1/2 HR 360 2,112.00 37010005 GEN SURG LEV 2 1ST HR 360 6,547.00 37010007 GEN SURG LEV 2 ADD 1/2 HR 360 3,273.00 37010009 GEN SURG LEV 3 1ST HR 360 8,325.00 37010010 GEN SURG LEV 3 ADD 1/2 HR 360 4,163.00 37010011 BAG AUTOTRANS ATRIUM 272 263.00 37010013 GEN SURG LEV 4 1ST HR 360 11,747.00 37010015 GEN SURG LEV 4 ADD 1/2 HR 360 5,874.00 37010019 GEN SURG LEV 5 ADD 1/2 HR 360 7,036.00 37010020 GEN SURG LEV 5 1ST HR 360 14,072.00 37010021 LITHOTRIPSY 1ST HR 790 7,672.00 37010023 LITHOTRIPSY ADD 1/2 HR 790 3,837.00 37010101 BLOOD TRANSFUSN 391 1,763.00 37010105 IV INF HYDRAT ADDL HR 260 305.00 37010107 IV INF EA ADDL HR 260 305.00 37010108 IV INF EA ADDL DRUG 260 339.00 37010116 CHEMO ADMIN IV PUSH INIT 331 687.00 37010117 CHEMO ADMIN IV PUSH ADD 331 418.00 37010118 CHEMO INF 1ST HR 335 1,071.00 37010119 CHEMO INF EA ADDL HR 335 415.00 37010121 CHEMO INF EA ADDL DRUG 335 631.00 37010231 US GUIDE NDL PLCMT S&I 402 1,008.00 37010233 US GUIDE VAD S&I 402 929.00 37010234 REP RECRRNT INCISI HERNIA 360 25,888.00 37010264 N BLCK INJ BRACHIAL PLEX 361 1,269.00 37010268 N BLCK INJ AXILLARY 361 1,269.00 37010270 N BLCK INJ SUPRASCAPULAR 361 1,269.00 37010282 N BLCK INJ SCIATIC SNG 361 1,269.00 37010284 N BLK INJ SCIATIC CONT IN 361 1,269.00 37010286 N BLCK INJ FEM SNGL 361 1,269.00 37010288 N BLCK INJ FEM CONT INF 361 1,269.00 37010292 N BLCK OTHER PERIPHERAL 361 1,269.00 37010294 N BLCK INJ PLANTAR DIGIT 361 1,269.00 37010295 IMPL/REPL SQ RSV EPID INF 361 8,793.00 37010300 BRONCH VISUAL OF WINDPIPE 361 2,328.00 37010301 DX BRONCHOSCPY/WASH 361 4,528.00 37010302 DX BRONCHSCPY/BRUSH 361 1,905.00 37010303 DX BRONCHOSCPY/LAVAGE 361 1,905.00 37010304 BRONCHOSCOPY W/BX 361 2,328.00 37010305 BRONCHSCPY/LUNG BX EACH 361 2,328.00 37010306 BRONCHSCPY/NDL BX EACH 361 2,328.00 37010307 BRONCHOSCPY/LUNG BX ADDTL 361 2,328.00 37010308 BRONCHSCPY/NDL BX ADDTL 361 2,328.00 37010309 AIRWAYS SURGICAL PROC 361 1,059.00 37010312 NJX INTERLAMINAR LMBR/SAC 361 1,220.00 37010313 EGD REM LESION W SNARE 361 6,064.00 37010314 COLSCPY FLX W/LES RMVL 361 6,064.00 37010828 BIT DRILL 2.5MM 310.25 272 572.00 37010832 BIT DRILL 3.5MM 310.35 272 606.00 37010837 DRILL BIT 310.63 5.0 CANC 272 2,432.00 37010838 BIT DRILL 310.65 3.2 CANC 272 2,417.00 37010839 BIT DRILL 310.67 2.7 CANN 272 2,457.00 37010840 BIT DRL 310.68 3.5 CAN QC 272 2,457.00 37010880 BLADE FULL RADIUS 2.9MM 272 416.00 37011106 LASR DSTR PROLF LESN<10CM 361 3,857.00 37011107 LASR DSTR PROLF LESN<50CM 361 3,857.00 37011108 LASR DSTR PROLF LESN>50CM 361 3,857.00 37011111 SKIN BIOPSY-DERMATOLOGY 361 794.00 37011112 REMOV SKIN LESION-SMPL 361 2,071.00 37011113 REMOV SKIN LESION-MODERAT 361 2,434.00 37011114 REMOV SKIN LESION-CMPLX 361 2,857.00 37011116 ESOPH REFLUX TEST PH NASL 750 1,905.00 37011117 ESOPH IMPED FNCTN TEST 750 1,905.00 37011118 ESOPH IMPED FNCTN TEST>1H 750 1,905.00 37011800 CHEMODNRV ANAL MUSC 361 424.00 37012004 TRACHEOBRONCH THRU TRACH 361 2,117.00 37012009 BRONCH W/WO CELL WASHING 361 2,328.00 37012010 DX BRONCHOSCOPE/BRUSH 361 2,509.00 37012014 BRONCH W BX 361 6,064.00 37012021 BRONCH TRACH/BRONCH DILAT 361 2,398.00 37012024 ESOPHAGOSCOPY BIOPSY 361 1,905.00 37012026 DILATE ESOPH UNGUID BOUGI 361 2,181.00 37012029 EGD BALLOON DILATION 361 3,214.00 37012034 EGD WIRE GUIDED DIL 361 3,214.00 37012039 UPPER EGD W/WO BRUSH/WASH 361 3,214.00 37012044 EGD BIOPSY 361 3,214.00 37012049 ESOPH SCOPE W/SCLEROS INJ 361 3,214.00 37012054 EGD DIL GASTRIC OUTLET OB 361 3,214.00 37012059 EGD TO PLACE PEG 361 3,214.00 37012064 EGD/REMOVAL FOREIGN BODY 361 3,214.00 37012069 EGD CONTROL OF BLEED 361 3,214.00 37012074 ERCP W/WO BRUSH 361 3,270.00 37012076 ERCP W/BX 361 3,175.00 37012079 ERCP/PAPILLOTOMY/SPHINCTE 361 4,604.00 37012081 ERCP W/ LITHO CALCULUS 361 3,175.00 37012084 ERCP RETRO INSRT STENT 361 3,270.00 37012085 ERCP REMOVE FB, STENT 361 3,270.00 37012086 ERCP BALLOON DILATION 361 3,270.00 37012089 G-TUBE CHNG 361 424.00 37012094 ILEOSCOPY THRU STOMA W/BI 361 2,858.00 37012099 PROCTOSIGMOID W/BX 361 1,905.00 37012104 SIGMOID W/BX 361 1,905.00 37012105 SIGMOIDOSCOPY W/RMVL FB 361 1,905.00 37012109 COLONOSCOPY W/WO BRUSH WA 361 2,434.00 37012114 COLONOSCOPY W/BX 361 3,286.00 37012115 COLONOSCOPY W/BLLN/STRICT 361 2,858.00 37012119 COLON REMOVE LESION SNARE 361 2,434.00 37012129 ANORECTAL MANOMETRY 750 1,977.00 37012134 RECTAL SUCTION BIOPSY 361 2,646.00 37012139 EGD GI TRACT PH PROBE 750 2,937.00 37012144 ESOPHAGEAL MANOMETRY 750 1,905.00 37012156 GI CAP ENDOSCOPY 750 3,704.00 37012159 BRONCH REMOVE FOREIGN BOD 361 2,328.00 37012164 EGD LIGATE ESOPH VARICES 361 3,214.00 37012174 COLON CONTROL OF BLEED 361 3,286.00 37012175 BX BONE MARR & ASP 361 1,588.00 37012179 COLON RMVL FB 361 2,434.00 37012189 COLON THRU STOMA W/BX 361 3,286.00 37012194 SIGMOID CONTROL OF BLEED 361 1,905.00 37012197 SCAN PROC CRANIAL INTRA 360 4,560.00 37012201 BRONCH W/ BAL/WASH 361 2,398.00 37012204 MINOR PROC 1ST 30MIN 361 1,363.00 37012205 MINOR PROC ADD 15MIN 361 662.00 37012324 BONE CANC CHIP 15CC 278 1,720.00 37012739 ENDO PEANUTS 5MM 272 180.00 37012835 REV EYE MUSC; 1 HORIZ MUS 360 11,022.00 37013001 ANESTH 1ST HR 370 1,542.00 37013003 ANESTH ADDL 1/2 HR 370 770.00 37013348 NAIL ELASTIC 475.920 2.0/ 278 1,723.00 37013349 NAIL ELASTIC 475.925 2.50 278 1,906.00 37013858 PLATE TIT 441.37 7H/85TBL 278 553.00 37013880 PLTE TUB 1/3 6H 241.36 7 278 388.00 37013882 PLTE TUB 1/3 8H 241.38 9 278 461.00 37013916 PORT REG 6.8FR R#060220 278 1,866.00 37014005 EXTND RECVRY/HR 710 144.00 37014205 SCRW CA 206.016 4.0/16 F 278 192.00 37014305 SCRW CA 205.018 3.5/18/6 278 1,379.00 37014306 SCRW CA 205.022 3.5/22/7 278 1,379.00 37014307 SCRW CA 205.026 3.5/26/8 278 1,379.00 37014308 SCRW CA 205.028 3.5/28/9 278 1,379.00 37014309 SCRW CA 205.030 3.5/30/10 278 1,379.00 37014310 SCRW CA 205.032 3.5/32/11 278 1,379.00 37014311 SCRW CA 205.034 3.5/34/11 278 1,379.00 37014312 SCRW CA 205.036 3.5/36/12 278 1,379.00 37014313 SCRW CA 205.038 3.5/38/12 278 1,379.00 37014314 SCRW CA 205.040 3.5/40/13 278 1,379.00 37014315 SCRW CA 205.044 3.5/44/14 278 1,379.00 37014316 SCRW CA 205.046 3.5/46/15 278 1,379.00 37014320 SCRW CA 205.220 3.5 278 1,379.00 37014321 SCRW CA 205.226 3.5/26 F 278 1,379.00 37014322 SCRW CA 205.232 3.5/32 F 278 1,379.00 37014326 SCRW CA 207.612 4.0/12 ST 278 1,181.00 37014327 SCRW CA 207.614 4.0/14 ST 278 1,243.00 37014328 SCRW CA 207.616 4.0/16 ST 278 1,454.00 37014329 SCRW CA 207.618 4.0/18 ST 278 1,181.00 37014330 SCRW CA 207.620 4.0/20 ST 278 1,345.00 37014331 SCRW CA 207.622 4.0/22 ST 278 1,345.00 37014332 SCRW CA 207.624 4.0/24 ST 278 1,345.00 37014333 SCRW CA 207.626 4.0/26 S 278 1,181.00 37014334 SCRW CA 207.628 4.0/28 S 278 1,181.00 37014335 SCRW CA 207.630 4.0/30 S 278 1,181.00 37014336 SCRW CA 207.632 4.0/32 S 278 1,454.00 37014337 SCRW CA 207.634 4.0/34 S 278 1,454.00 37014338 SCRW CA 207.636 4.0/36 S 278 1,454.00 37014339 SCRW CA 207.638 4.0/38 S 278 1,454.00 37014340 SCRW CA 207.640 4/40 ST 278 1,454.00 37014341 SCRW CA 207.642 4/42 ST 278 1,454.00 37014342 SCRW CA 207.644 4.0/44 S 278 1,454.00 37014343 SCRW CA 207.646 4.0/46 S 278 1,454.00 37014344 SCRW CA 207.650 4.0/50 S 278 1,454.00 37014345 SCRW CA 207.716 4.0/16 278 1,181.00 37014348 SCRW CA 207.722 4.0/22 278 1,038.00 37014349 SCRW CA 207.724 4.0/24 278 874.00 37014350 SCRW CA 207.726 4.0/26 278 1,181.00 37014351 SCRW CA 207.728 4.0/28 278 1,181.00 37014352 SCRW CA 207.730 4.0/30 278 1,181.00 37014353 SCRW CA 207.732 4.0/32 278 1,181.00 37014354 SCRW CA 207.734 4.0/34 278 1,379.00 37014355 SCRW CA 207.736 4.0/36 278 1,345.00 37014356 SCRW CA 207.738 4/38 278 1,181.00 37014357 SCRW CA 207.740 4.0/40 278 1,454.00 37014359 SCRW CA 207.746 4.0/46 278 1,345.00 37014360 SCRW CA 207.748 4.0/48 278 1,181.00 37014361 SCRW CA 207.750 4.0/50 278 1,242.00 37014392 SCRW CA 208.905 7.3/105 278 1,218.00 37014393 SCRW CA 208.910 7.3/110 278 1,368.00 37014394 SCRW CA 208.915 7.3/115 278 1,368.00 37014395 SCRW CA 208.920 7.3/120 278 1,368.00 37014440 SCRW CA 214.544 4.5/44/15 278 1,254.00 37014442 SCRW CA 214.548 4.5/48 PT 278 1,393.00 37014444 SCRW CA 214.552 4.5/52 278 1,393.00 37014446 SCRW CA 214.556 4.5/56/19 278 1,393.00 37014447 SCRW CA 214.560 4.5/60/20 278 1,254.00 37014521 SCRW CTX 204.812 3.5/12 S 278 202.00 37014522 SCRW CTX 204.814 3.5/14 S 278 202.00 37014523 SCRW CTX 204.816 3.5/16 S 278 202.00 37014524 SCRW CTX 204.818 3.5/18 S 278 202.00 37014525 SCRW CTX 204.820 3.5/20 S 278 202.00 37014526 SCRW CTX 204.822 3.5/22 S 278 202.00 37014687 SCREW 3.5MM TIT CTX 12MM 278 223.00 37014688 SCREW 3.5MM TIT CTX 14MM 278 223.00 37014689 SCREW 3.5MM TIT CTX 16MM 278 223.00 37014826 ENDOSHEAR MINI 5MM 272 473.00 37015001 PACU 1ST HR 710 2,164.00 37015003 PACU EA ADDL 1/2 HR 710 1,083.00 37015005 OPTIRAY 300-399 EA ML 636 4.00 37015480 STIMULATOR NERVE VARI STM 272 428.00 37015509 CAST 2 272 29.00 37015510 CAST 3IN BLUE FIBERGLASS 272 29.00 37015627 TUBE FEEDING 6F 272 99.00 37015891 WASHER 10.0 219.91 278 246.00 37015892 WASHER 13.0 219.99 LG 278 253.00 37015893 WASHER 7.0 219.98 SM 278 242.00 37015923 WIRE GUID 292.62 1.25 TH 278 276.00 37015927 WIRE GUID 292.68 2.8 THR 278 400.00 37015929 WIRE GUID 292.72 1.6/150T 278 312.00 37017416 SPONGE GELFOAM 100 272 376.00 37017741 NDL BX BONE MARROW PEDS 272 137.00 37017833 NDL INSUFFLATION 14G/100 272 153.00 37017942 PACK CYSTOSCOPY BASIC 272 165.00 37018819 TIP NDL MICRO BOVIE 272 415.00 37019000 ISOVUE300-61%-50ML PER ML 636 9.00 37019198
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Enhancing Transdermal Delivery of Opioid Antagonists and Agonists Using Codrugs Linked to Bupropion Or Hydroxybupropion Audra L
    University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 2-18-2014 Enhancing Transdermal Delivery of Opioid Antagonists and Agonists Using Codrugs Linked To Bupropion or Hydroxybupropion Audra L. Stinchcomb University of Kentucky Peter A. Crooks University of Kentucky, [email protected] Mohamad O. Hamad University of Kentucky, [email protected] Paul K. Kiptoo University of Kentucky Click here to let us know how access to this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Stinchcomb, Audra L.; Crooks, Peter A.; Hamad, Mohamad O.; and Kiptoo, Paul K., "Enhancing Transdermal Delivery of Opioid Antagonists and Agonists Using Codrugs Linked To Bupropion or Hydroxybupropion" (2014). Pharmaceutical Sciences Faculty Patents. 27. https://uknowledge.uky.edu/ps_patents/27 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US008653271B2 (12) United States Patent (10) Patent N0.: US 8,653,271 B2 Stinchcomb et a]. (45) Date of Patent: Feb. 18, 2014 (54) ENHANCING TRANSDERMAL DELIVERY (58) Field of Classi?cation Search OF OPIOID ANTAGONISTS AND AGONISTS USPC ............................... .. 546/45, 44, 46; 514/282 USING CODRUGS LINKED TO BUPROPION See application ?le for complete search history. OR HYDROXYBUPROPION (56) References Cited (75) Inventors: Audra L. Stinchcomb, Lexington, KY (US); Peter A. Crooks, Nicholasville, U.S. PATENT DOCUMENTS KY (US); Mohamed O. Hamad, Lexington, KY (US); Paul K.
    [Show full text]
  • Detection and Characterization of Pyromarkers of Smoked Drugs of Abuse
    Graduate Theses, Dissertations, and Problem Reports 2012 Detection and characterization of pyromarkers of smoked drugs of abuse Rona Kiyomi Nishikawa West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Nishikawa, Rona Kiyomi, "Detection and characterization of pyromarkers of smoked drugs of abuse" (2012). Graduate Theses, Dissertations, and Problem Reports. 4904. https://researchrepository.wvu.edu/etd/4904 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. DETECTION AND CHARACTERIZATION OF PYROMARKERS OF SMOKED DRUGS OF ABUSE Rona Kiyomi Nishikawa Dissertation submitted to the Eberly College of Arts and Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Chemistry Committee of Advisors: Suzanne C. Bell, Ph.D., Chair R. Lloyd Carroll, Ph.D. Patrick S. Callery, Ph.D. Harry O. Finklea, Ph.D. Keith B. Morris, Ph.D. C. Eugene Bennett Department of Chemistry Morgantown, West Virginia 2012 Keywords: Fentanyl, Heroin, Pyrolysis, Pyromarkers, GC/MS Copyright © 2012 Rona Kiyomi Nishikawa 1 Abstract DETECTION AND CHARACTERIZATION OF PYROMARKERS OF SMOKED DRUGS OF ABUSE Rona Kiyomi Nishikawa Smoking or inhalation has increased in popularity as the choice route of administration of drugs of abuse amongst drug abusers.
    [Show full text]
  • Synthesis and Characterization of TPGS–Gemcitabine Prodrug
    RSC Advances View Article Online PAPER View Journal | View Issue Synthesis and characterization of TPGS– gemcitabine prodrug micelles for pancreatic Cite this: RSC Adv.,2016,6,60126 cancer therapy† Vaibhav Khare,ab Wejdan Al. Sakarchi,a Prem N. Gupta,b Anthony D. M. Curtisa and Clare Hoskins*a The therapeutic potential of a nucleoside analog, gemcitabine, is severely compromised due to its rapid clearance from systemic circulation by enzymatic degradation into an inactive metabolite. In the present investigation, micelles based on polymer–drug conjugate were developed for gemcitabine and investigated for their potential to improve cancer chemotherapy. The tocopherol poly(ethylene glycol) succinate 1000 (TPGS)–gemcitabine prodrug was synthesized via an amide linkage and characterised by analytical methods, including FT-IR, 1H NMR, and MALDI-TOF. The micellar formulation of TPGS– gemcitabine prodrug was developed by a self-assembly technique and evaluated for various Creative Commons Attribution-NonCommercial 3.0 Unported Licence. physicochemical parameters including particle size, polydispersity, morphology, critical micelle concentration and release profile. It was observed that gemcitabine present in TPGS–gemcitabine micelles was resistant to deamination by crude cytidine deaminase. The improved cytotoxicity of the micellar formulation was observed using TPGS–gemcitabine micelles against pancreatic cancer cells. Received 11th April 2016 Further, it was found that, unlike native gemcitabine, nucleoside transporters were not required for Accepted 14th June 2016 TPGS–Gem micelles to demonstrate their anticancer potential. These findings revealed that TPGS– DOI: 10.1039/c6ra09347g gemcitabine micelles may serve as a promising platform for gemcitabine in order to improve its www.rsc.org/advances anticancer efficacy.
    [Show full text]
  • Claire Cole, Lisa Jones, Jim Mcveigh, Andrew Kicman, Qutub Syed & Mark A
    Claire Cole, Lisa Jones, Jim McVeigh, Andrew Kicman, Qutub Syed & Mark A. Bellis Acknowledgements The authors would like to thank the following for their contribution to the literature searching, design, proofing, editing and distribution of this document: Carol Chadwick. Sian Connolly, Layla English, Michael Evans-Brown, Dave Seddon, Olivia Wooding, Lee Tisdall, Ellie McCoy and Gemma Parry of the Centre for Public Health. We would also like to thank the International Harm Reduction Association (IHRA) for their support with launching this report at their 2010 conference. About the Authors Claire Cole and Lisa Jones are Senior Researchers at the Centre for Public Health, Liverpool John Moores University. Jim McVeigh is the Deputy Director and Reader in Substance Use Epidemiology at the Centre for Public Health. Professor Andrew Kicman is Head of Research and Development in the Department of Forensic Science and Drug Monitoring, The Drug Control Centre, at Kings College London. Professor Qutub Syed is the Regional Director for Health Protection Agency in the North West Region. Professor Mark A. Bellis is the Director of the Centre for Public Health. 1 Contents Executive Summary 4 1. Introduction 10 2. Methodology 13 3. Heroin 17 4. Cocaine and Crack Cocaine 25 5. Amphetamine and Methamphetamine 30 6. Ecstasy 33 7. Cannabis 36 8. Other Illicit Drugs 38 9. Public Health Response and Harm Reduction Messages 40 10. Summary 45 References 47 Appendix 1 - Glossary 55 List of Tables Table 1: Summary of drug adulteration evidence 5 Table 2: Summary
    [Show full text]
  • Prodrug Derivatives of Carboxylic Acid Drugs
    Patentamt JEuropaischesEuropean Patent Office Office europeen des brevets © Publication number: 0 278 977 B1 © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification : © Int. CI.5 : C07C 233/01, A61 K 31/21 06.05.92 Bulletin 92/19 © Application number : 87905946.7 @ Date of filing : 25.08.87 © International application number : PCT/DK87/00104 @ International publication number : WO 88/01615 10.03.88 Gazette 88/06 (54) PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS. The file contains technical information (56) References cited : submitted after the application was filed and US-A- 4 588 525 not included in this specification US-A- 4 678 806 CHEMICAL ABSTRACTS, vol. 106, 1987, ab- stract no. 781 87t, 16 March 1987; H. © 26.08.86 DK 4066/86 Priority : BUNDGAARD et al, Esters of N,N-disub- stituted2-hydroxyacetamides as a novel high- © Date of publication of application : ly biolabile prodrug type for carboxylic acid 24.08.88 Bulletin 88/34 agents'' © Publication of the grant of the patent : © Proprietor : Bundgaard, Hans 06.05.92 Bulletin 92/19 36, Tjornevej DK-2970 Horsholm (DK) Niels Mork States Proprietor : NIELSEN, © Designated Contracting : st.th. AT BE CH DE FR GB IT LI LU NL SE Cumberlandsgade 15, DK-2300 Kobenhavn S (DK) References cited 56 : Inventor Hans EP-A- 0 073 397 © : Bundgaard, EP-A- 077 720 36, Tjornevej DK-2970 Horsholm EP-A- 106 541 (DK) Inventor : NIELSEN, Niels Mork EP-A- 201 829 st.th. EP-A- 224 178 Cumberlandsgade 15, DK-2300 Kobenhavn S EP-A- 227 355 (DK) EP-A- 237 051 WO-A-86/00066 © Representative : Andersen, Henrik Rastrup et CH-A- 513 815 al US-A- 4 206 220 c/o Plougmann & Vingtoft Sankt Annae Plads US-A- 4 235 887 11 P.O.
    [Show full text]
  • Procedure Code
    Procedure Code Description Revenue Code Charge 61413012 ADJUSTMENT M/S PEDS 113 3,251.00 61413021 ADJUST TELM/PULM/NURO/ORT 113 6,653.00 61713103 ADJ M/S PEDS 113 3,251.00 61716119 M/S PEDS - PRIVATE 113 3,626.00 61801013 ADJ M/S PEDS 113 3,251.00 61802019 ADJ BMT ACUTE 113 6,653.00 62067021 M/S PEDS - PRIVATE 113 3,626.00 62093001 M/S PEDS - PRIVATE 113 3,626.00 62093011 ADJ M/S PEDS 113 3,251.00 62093013 ADJ TELEM/PULM/TRACH/NURO 113 6,653.00 62123001 M/S PEDS - PRIVATE 113 3,626.00 62123011 ADJ M/S PEDS 113 3,251.00 62133003 M/S PEDS - PRIVATE 113 3,626.00 62133013 ADJ M/S PEDS 113 3,251.00 62153003 M/S PEDS - PRIVATE 113 3,626.00 62153013 ADJ M/S PEDS 113 3,251.00 62153015 ADJ TELEM/PULM/TRACH/NURO 113 6,653.00 62183003 M/S PEDS - PRIVATE 113 3,626.00 62183013 ADJ M/S PEDS 113 3,251.00 62183017 ADJ TELEM/PULM/TRAC/NURO 113 6,653.00 62211003 M/S PEDS - PRIVATE 113 3,626.00 62211015 ADJ M/S PEDS 113 3,251.00 62212001 MS/PEDS - BMT HIP 113 6,160.00 62212011 ADJ BMT-ACUTE CARE 113 6,653.00 62213001 M/S PEDS HEMONC 113 3,626.00 62213011 ADJ M/S HEM ONC 113 6,653.00 62214015 ADJ M/S CARDIAC MONITORNG 113 6,653.00 62243003 M/S PEDS - PRIVATE 113 3,626.00 62243011 ADJ TELEM/PULM/TRAC/NURO 113 6,653.00 62243013 ADJ M/S PEDS 113 3,251.00 62253003 M/S PEDS - PRIVATE 113 3,626.00 62253011 ADJ TELM/PULM/NURO/OBS 113 6,653.00 62253013 ADJ M/S PEDS 113 3,251.00 62263003 M/S PEDS - PRIVATE 113 3,626.00 62263011 ADJ TELEM/PULM/TRAC/NURO 113 6,653.00 62263013 ADJ M/S PEDS 113 3,251.00 72309250 M/S PEDS - PRIVATE 113 3,626.00 72309252 ADJ EDA ACUTE 113
    [Show full text]
  • ED 042 219 DOCUMENT RESUME CG 005 800 the Development of A
    DOCUMENT RESUME ED 042 219 24 CG 005 800 TITLE The Development of a Curriculum for Teaching Elementary and Secondary School Children the Dangers Inherent in the Use and Abuse of Dangerous Drugs. Final Progress Report. INSTITUTION Laredo Independent School District, Tex. SPONS AGENCY Office of Education (DHEW) ,Washington, D.C. BUREATI NO BR-9-G-067 PUB DATE 30 Sep 70 CONTRACT OEC -7 -9- 530067 -0123- (010) NOTE 545p.; Second Edition EDRS PRICE EDRS Price MF-$2.00 HC-$27.35 DESCRIPTORS *Curriculum Development, *Curriculum Guides, *Drug Abuse, Elementary School Students, Instructional Materials, Secondary School Students, *Social Problems, *Teaching Guides ABSTRACT This very extensive guide, designed in large measure by classroom teachers an' meant for use by classroom teachers, is one community's response to its drug problem. The completed guide, however, is designed for adaptation throughout the nation and in foreign countries. Material is offered for different school levels, with the primary grades receiving information introduced by the classroom teacher, focusing on mental health and character development. The concept of drugs as medicine and narcotics is presented at the upper elementary level. The approach in the secondary grades is through the established curriculum with units offered in English, Mathematics, Science, Health and Physical Education and Social Studies. Specific yet flexible guidelines are included at each grade level to help establish objectives, create motivation, and provide activities for enrichment and reinforcement. Glossaries and factual information which can help answer questions often asked are included, as well as letters to committee members and parents. (CJ) Laredo Independent School District C\I C\J CD W THE USE, MISUSE, AND ABUSE OF DRUGS AND NARCOTICS SECOND EDITION r-4 CV CV O Final Progress Report Proposal No.
    [Show full text]
  • (EUA) of VEKLURY® (Remdesivir) for HOSPITALIZED PEDIATRIC
    FACT SHEET FOR HEALTHCARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF VEKLURY® (remdesivir) FOR HOSPITALIZED PEDIATRIC PATIENTS WEIGHING 3.5 KG TO LESS THAN 40 KG OR HOSPITALIZED PEDIATRIC PATIENTS LESS THAN 12 YEARS OF AGE WEIGHING AT LEAST 3.5 KG The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of VEKLURY for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. VEKLURY has been authorized by FDA for the emergency uses described above. VEKLURY is not FDA-approved for these uses. VEKLURY is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of VEKLURY under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. This EUA is for the use of VEKLURY to treat COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. VEKLURY must be administered by intravenous (IV) infusion. Healthcare providers must submit a report on all medication errors and ALL SERIOUS ADVERSE EVENTS related to VEKLURY. See Sections 8 and 9 of the Full EUA Prescribing Information for reporting requirements. • See the Full EUA Prescribing Information for complete dosage, preparation, and administration instructions.
    [Show full text]
  • Forensic Pharmacology__Inside
    INSIDE FORENSIC SCIENCE Forensic Pharmacology INSIDE FORENSIC SCIENCE Forensic Anthropology Forensic DNA Analysis Forensic Medicine Forensic Pharmacology Legal Aspects of Forensics The Forensic Aspects of Poisons INSIDE FORENSIC SCIENCE Forensic Pharmacology Beth E. Zedeck, MSW, RN, MSN and Morris S. Zedeck, Ph.D. SERIES EDITOR | Lawrence Kobilinsky, Ph.D. The authors are proud to have worked as a father and daughter team on this project and wish to thank Dr. Zedeck’s wife, Ellen Lieberman, Esq., for her assistance and thoughtful suggestions during the preparation of this book. Forensic Pharmacology Copyright © 2007 by Infobase Publishing All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval systems, without permission in writing from the publisher. For information contact: Chelsea House An imprint of Infobase Publishing 132 West 31st Street New York NY 10001 Library of Congress Cataloging-in-Publication Data Zedeck, Beth E. Forensic pharmacology / Beth E. Zedeck and Morris S. Zedeck. p. cm. — (Inside forensic science) Includes bibliographical references and index. ISBN 0-7910-8920-7 (hardcover) 1. Forensic pharmacology. I. Zedeck, Morris S. II. Title. RA1160.Z43 2006 614'.1—dc22 2006020624 Chelsea House books are available at special discounts when purchased in bulk quantities for businesses, associations, institutions, or sales promotions. Please call our Special Sales Department in New York at (212) 967-8800 or (800) 322-8755. You can find Chelsea House on the World Wide Web at http://www.chelseahouse.com Cover design by Ben Peterson Text design by Annie O’Donnell Printed in the United States of America BANG FOF 10 9 8 7 6 5 4 3 2 1 This book is printed on acid-free paper.
    [Show full text]
  • Prescribing Information for RISPERDAL CONSTA
    RISPERDAL CONSTA® RISPERDAL CONSTA® (risperidone) LONG-ACTING INJECTION (risperidone) LONG-ACTING INJECTION • Hyperprolactinemia: Risperidone treatment may elevate prolactin levels. Long- HIGHLIGHTS OF PRESCRIBING INFORMATION standing hyperprolactinemia, when associated with hypogonadism, can lead These highlights do not include all the information needed to use to decreased bone density in men and women. (5.6) RISPERDAL CONSTA® safely and effectively. See full prescribing information • Orthostatic hypotension: associated with dizziness, tachycardia, bradycardia, for RISPERDAL CONSTA®. and syncope can occur, especially during initial dose titration with oral RISPERDAL CONSTA® (risperidone) LONG-ACTING INJECTION risperidone. Use caution in patients with cardiovascular disease, cerebrovascular disease, and conditions that could affect hemodynamic Initial U.S. Approval: 2003 responses. (5.7) • Leukopenia, Neutropenia, and Agranulocytosis have been reported with WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS antipsychotics, including RISPERDAL CONSTA®. Patients with history of a WITH DEMENTIA-RELATED PSYCHOSIS clinically significant low white blood cell count (WBC) or a drug-induced See full prescribing information for complete boxed warning. leukopenia/neutropenia should have their complete blood cell count (CBC) Elderly patients with dementia-related psychosis treated with antipsychotic monitored frequently during the first few months of therapy and drugs are at an increased risk of death. RISPERDAL CONSTA® is not approved discontinuation of RISPERDAL CONSTA® should be considered at the first sign for use in patients with dementia-related psychosis. (5.1) of a clinically significant decline in WBC in the absence of other causative factors. (5.9) • Potential for cognitive and motor impairment: has potential to impair judgment, ---------------------------------RECENT MAJOR CHANGES-------------------------------- thinking, and motor skills. Use caution when operating machinery, including Warnings and Precautions (5.3, 5.4) 2/2021 automobiles.
    [Show full text]
  • RISPERDAL CONSTA® Risperidone NEW ZEALAND DATA SHEET
    RISPERDAL CONSTA® risperidone NEW ZEALAND DATA SHEET 1. PRODUCT NAME RISPERDAL CONSTA 25 mg/2 ml Suspension for injection RISPERDAL CONSTA 37.5 mg/2 ml Suspension for injection RISPERDAL CONSTA 50 mg/2 ml Suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION RISPERDAL CONSTA is an extended release microspheres formulation of risperidone micro- encapsulated in polyglactin for intramuscular injection, in strengths of 25mg, 37.5mg and 50mg when suspended in 2mL diluent. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for prolonged-release suspension for injection. RISPERDAL CONSTA contains either 25 mg, 37.5 mg or 50 mg risperidone and is presented as a white to off-white free-flowing powder in a 5mL vial and a prefilled syringe containing 2mL diluent, together with: - One Vial Adapter for reconstitution (referred as Vial Adapter), and - Two Terumo SurGuard needles for intramuscular injection (a 21G UTW 1-inch safety needle with needle protection device for deltoid administration and a 20G TW 2-inch safety needle with needle protection device for gluteal administration). 4. CLINICAL PARTICULARS 4.1 Therapeutic indications RISPERDAL CONSTA is indicated for the treatment of schizophrenia and other psychotic disorders. These include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. RISPERDAL CONSTA also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. In addition, RISPERDAL CONSTA also appears effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial response to treatment with this agent.
    [Show full text]